ClinicalTrials.gg
CompletedNCT04423120Updated May 22, 2024

Clinical Study on a Novel Minimally Invasive Posterior Sacroiliac Fusion Device

An observational study in Chronic Pain, sponsored by PainTEQ, LLC. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by PainTEQ, LLC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
159
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
81st of 189
159 · median 100
Started
2020
with 79 others
Observational
189 of 1,283
46 open now
Registered
665th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 81st largest by enrollment of the 189 observational ones that give a count, is one of 80 that started in 2020, is one of 189 observational ones, and was the 665th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

The PainTEQ study is a prospective, multi-site, prospective, single arm study intended to collect clinical data outcomes data associated with the treatment of sacroiliac disease with the LinQ fusion procedure. Data will be collected using self-report measures including the visual analog scale (VAS) for pain assessment where the participant is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. Other self-report questionnaires will be administered including the Oswestry Disablity Index (ODI) to measure low-back pain and disability, and the Patient-Reported Outcomes Measurement Information System 29 (PROMIS 29) to measure physical, mental, and social health and well-being.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential study participants will come from the existing patient population of the investigators in each individual practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21-70
  • Patient has lower back pain for >6 months inadequately responsive to conservative care
  • Patient has at least 3 of 4 physical examination maneuvers specific for the SI joint (FABER, Gaenslen test, Stork/Gillete, and Yoman)
  • Patient has improvement in lower back pain numeric rating scale (NRS) of at least 50% after injection of local anesthetic into affected SI joint(s) with confirmed arthrogram, within 30-60 min from injection
  • Degenerative sacroiliitis as SIJ mediated in in the context of either radiographic evidence of SIJ degeneration, evident on computed tomography or Xrays or a history of prior lumbar fusion.
  • SIJ disruption was defined in the study of as SIJ mediated pain in the context of asymmetric widening of SIJ on CT or Xrays or the presence of significant contrast leakage during diagnostic SIJ block
  • Baseline Oswestry Disability Index (ODI) score of at least 30%
  • Baseline Low back/buttock pain score of at least 50 on 0-100 mm visual analog scale
  • Patient has signed study-specific form
  • Patient has the necessary mental capacity to consent and participate and is physically able to comply with study protocol requirements
  • Patient has medical insurance that covers this standard of care procedure and all other anticipated and unanticipated procedure related care.
  • Patient's physician has decided that the best treatment for the patient's sacro-iliac disease is the LinQ system and the patient has agreed to the treatment.

Exclusion criteria

Exclusion Criteria:

  • Inability to confirm that the pain is arising from the sacroiliac joint
  • Current severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar radicular pain, and lumbar vertebral body fracture
  • SIJ pain secondary to inflammatory conditions, Other known sacroiliac pathology such as: Sacral dysplasia, Inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondylo-arthropathy), Tumor, Infection, Acute fracture, and Crystal arthropathy.
  • Radicular pain extending beyond the buttock ≥ 30mm on VAS
  • Has complete resolution of pain from the diagnostic SIJ injection lasting 30 days or more
  • Has had an injection with into the index SIJ within the last 90 days
  • Has had any neuraxial injection with corticosteroid within the last 90 days
  • Has greater than 50% pain relief from diagnostic medial branch blocks at the L4/5 and/or L5/S1 levels
  • Has had a sacral radiofrequency ablation within the last 6 months
  • History of any hardware placement within the sacrum or sacroiliac joint
  • History of coccydynia or coccygectomy
  • Clinical diagnosis of discogenic pain at L4/5 and/or L5/S1
  • History of endometriosis or pudendal neuralgia
  • History of recent (\<1 year) major trauma to pelvis
  • Chronic rheumatologic condition (e.g., rheumatoid arthritis)
  • Any condition or anatomy that makes treatment with the Linq Implant System infeasible
  • Use of medications known to have detrimental effects on bone quality and soft-tissue healing (metabolic bone disease, induced or idiopathic)
  • Prominent neurologic condition that would interfere with physical therapy
  • Current local or systemic infection that raises the risk of surgery
  • Patient currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation.
  • Patient is participating in an study or has been involved in an investigational study within 3 months prior to evaluation for participation
  • Patient with insurance coverage that does not cover the SI fusion*
  • Implanted intrathecal pain pump
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
159 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change from baseline VAS Sacroiliac Joint (SIJ) pain by at least 20 millimeters

    A subject was considered a success if all of the following criteria were met 1. Change from baseline VAS SIJ pain by at least 20 mm (Binary success failure composite end point) VAS is a vertical scale, where a higher score depicts more pain (100 mm maximum) and a lower scale depicts less pain (0 mm minimum)

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  2. Absence of device related serious adverse events

    A subject was considered a success if all of the following criteria were met 2. Absence of device related serious adverse events, (Binary success failure composite end point)

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  3. Absence of neurological worsening related to the lumbosacral nerve roots

    A subject was considered a success if all of the following criteria were met 3. Absence of neurological worsening related to the lumbosacral nerve roots, (Binary success failure composite end point)

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  4. Absence of surgical reintervention (removal, revision reoperation or supplemental fixation) for SIJ pain

    A subject was considered a success if all of the following criteria were met 4. Absence of surgical reintervention (removal, revision reoperation or supplemental fixation) for SIJ pain (Binary success failure composite end point)

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

Secondary outcomes

  1. Change in VAS

    1. Change in baseline in VAS from baseline at 6 months

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  2. Change in ODI

    2. Change in Oswestry Disability Index at 6 months follow up ODI assesses disability and has 10 sections, each with a point range from 0 (minimum) to 5 (maximum). A higher score translates to a higher percentage, meaning more disability (100% maximum). A lower score translates to a lower percentage, meaning less disability (0% minimum).

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  3. Change in PROMIS29

    3. Change in PROMIS-29 at 6 months follow up. PROMIS 29 assesses pain intensity using a 0-10 numeric rating scale (11 point scale), where a higher score equates to more pain. Other health domains are scored using a Likert scale, where higher scores represent more of the specific domain being measured.

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  4. Change in Patient Global Impression of Change (PGIC)

    4. Change in Patient Satisfaction with PGIC PGIC is on a 7 point scale that depicts a patient's rating on their overall improvement. A lower score translates to a profound improvement and a higher score translates to a salvage improvement.

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

  5. Change in Morphine milligram equivalent

    5. Change in MME usage at all time points

    Time frame: Comparisons will be done prior to baseline visit and 7-14 days post surgery, 1 month, 3 month, 6 month, and 12 month visits.

07

Study locations

1 site
  • Precision Spine Care
    Tyler, Texas 75701, United States
08

References and documents

Publications

  • Calodney A, Azeem N, Buchanan P, Skaribas I, Antony A, Kim C, Girardi G, Vu C, Bovinet C, Vogel R, Li S, Jassal N, Josephson Y, Lubenow T, Lam CM, Deer TR. Safety, Efficacy, and Durability of Outcomes: Results from SECURE: A Single Arm, Multicenter, Prospective, Clinical Study on a Minimally Invasive Posterior Sacroiliac Fusion Allograft Implant. J Pain Res. 2024 Mar 20;17:1209-1222. doi: 10.2147/JPR.S458334. eCollection 2024. PubMed 38524688 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Apr 2023, 37 months.

Of 363 observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2020
First posted
Jun 9, 2020
StartActual
Mar 13, 2020
Primary completionActual
Apr 30, 2023
CompletionActual
Apr 30, 2023
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04423120
Lead sponsor
PainTEQ, LLC
Collaborators
Pacific Research Institute
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Mar 13, 2020
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023
Last update
May 22, 2024

Study contacts

Aaron Calodeny, MD
principal investigator · Precision Spine Care

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion